Table 3.
IC50 values of heterocyclic derivatives against HT29, NCI H1299 and UM-UC3 cell lines.
| Entry | Compound | HT29[a] [IC50 in μM] | NCI—H1299[b] [IC50 in μM] | UM-UC3[c] [IC50 in μM] |
|---|---|---|---|---|
| 1 | KUNB31 [d] | 3.7 ± 0.34 | Not tested | 3.01 ± 0.56 |
| 2 | 5 | 18.84 ± 2.6 | 17.54 ± 0.42 | 71.63 ± 3.73 |
| 3 | 18 | 61.95 ± 1.42 | > 100 | > 100 |
| 4 | 19 | > 100 | > 100 | > 100 |
| 5 | 20 | > 100 | 74.99 ± 21.4 | > 100 |
| 6 | 21 | 93.74 ± 2.67 | 59.96 ± 10.5 | 52.95 ± 3.32 |
| 7 | 29 a | 63.54 ± 1.69 | 67.62 ± 4.13 | > 100 |
| 8 | 29 b | 21.72 ± 2.60 | 10.02 ± 3.28 | 55.55 ± 1.34 |
| 9 | 31 | 59.33 ± 0.18 | 58.10 ± 0.34 | 57.4 ± 13.68 |
| 10 | 32 a | 51.79 ± 2.18 | 46.13 ± 1.11 | 51.3 ± 1.83 |
| 11 | 32 b | 47.35 ± 2.94 | 41.39 ± 1.20 | 59.4 ± 4.8 |
| 12 | 40 | 60.25 ± 0.63 | 59.04 ± 1.78 | 70.4 ± 0.77 |
| 13 | 41 | 54.33 ± 1.32 | 51.31 ± 0.15 | 51.9 ± 1.27 |
| 14 | 42 | 58.29 ± 1.51 | 20.6 ± 0.28 | 69.9 ± 0.77 |
| 15 | 43 | > 100 | > 100 | > 100 |
| 16 | 44 | 75.29 ± 0.66 | 57.76 ± 8.01 | 59.65 ± 0.21 |
| 17 | 45 | Not tested | Not tested | Not tested |
| 18 | 46 | 66.52 ± 1.35 | 68.2 ± 1.20 | > 100 |
| 19 | 50 | 2.33 ± 0.48 | 1.53 ± 0.16 | 1.18 ± 0.1 |
| 20 | 51 | 51.17 ± 2.23 | 33.73 ± 1.78 | 51.65 ± 3.32 |
| 21 | 52 | 51.17 ± 2.23 | 85.95 ± 7.7 | 78.25 ± 15.7 |
| 22 | 59 a | 51.17 ± 2.23 | 83.33 ± 1.31 | > 100 |
| 23 | 59 b | Not tested | Not tested | Not tested |
colon cancer cell line
non-small cell lung carcinoma cell line
bladder cancer cell line.
KUNB31 IC50 values were taken from Ref. [27].